Search

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

12.82 -2.95

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

12.79

Massimo

13.18

Metriche Chiave

By Trading Economics

Entrata

-8.9M

-8M

Vendite

3.7M

139M

P/E

Media del settore

142.7

50.373

Margine di Profitto

-5.724

Dipendenti

1,790

EBITDA

18M

4M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+38.78% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

568M

2.5B

Apertura precedente

15.77

Chiusura precedente

12.82

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

31 ott 2026, 00:02 UTC

News

Lyft, Inc. shares are advancing in after-market trading, supported by a broader market uptick.

31 ott 2026, 00:02 UTC

Social Media
Correlated Moves
News

MSCI Inc. will continue using regular trading hours closing prices for index calculations, despite updates on trading extensions from Nasdaq and NYSE Arca.

31 ott 2026, 00:02 UTC

Correlated Moves
News

Cantor Fitzgerald identifies buying opportunity in crypto-linked stocks, including Strategy Inc, following Binance hack, noting potential for recovery as panic subsides.

31 ott 2026, 00:02 UTC

Correlated Moves
News

Allegro Microsystems Inc reported Q2 FY27 sales of $276.88 million and net income of $23.26 million, with shares trading higher in after-market hours.

31 ott 2026, 00:02 UTC

News

Okta, Inc. will replace Kenvue in the S&P 500 on November 4, 2026, following Kimberly-Clark's acquisition, enhancing its visibility to investors.

31 ott 2026, 00:02 UTC

News

DICK'S Sporting Goods faces class action lawsuits alleging securities fraud and misleading investors about financial performance following an earnings miss.

31 ott 2026, 00:02 UTC

News
Social Media

Coinbase Global, Inc. saw an uptick in after-market trading after JP Morgan maintained its Overweight rating but lowered the price target to $187.

31 ott 2026, 00:01 UTC

News

Mondelez International, Inc. shares traded modestly lower during after-market hours on Friday, following a decline from a brief peak earlier in the session.

31 ott 2026, 00:01 UTC

News

Kimberly-Clark Corporation is set to acquire Kenvue, with the transaction expected to close soon, subject to final conditions.

31 ott 2026, 00:01 UTC

News

Kraft Heinz Company shares advanced in after-market trading, reaching their highest point since Friday's close and trading near the upper end of their one-month range.

31 ott 2026, 00:01 UTC

News

BTIG suspended its Buy rating on IDEXX Laboratories, contributing to a decline in its share price during after-market hours.

31 ott 2026, 00:01 UTC

News

Ares Capital Corporation announced a merger agreement to acquire MidCap Financial Investment Corporation, resulting in the cancellation of MidCap's earnings call on November 5, 2026.

31 ott 2026, 00:01 UTC

News

BWX Technologies Inc is rising in after-market trading after being selected by the U.S. Army to develop a nuclear microreactor for its $2.2 billion Janus program.

30 ott 2026, 23:51 UTC

News

FMC Corp shares are declining in after-market hours following disappointing Q3 earnings, with an 80% revenue drop to $106 million and an adjusted loss per share of $4.41.

30 ott 2026, 23:51 UTC

News

BTIG suspended its Buy rating on Zoetis Inc, contributing to a modest decline in the stock during after-market hours.

30 ott 2026, 23:51 UTC

News

Stryker receives mixed analyst assessments, with Stifel lowering its price target to $325 and Citigroup adjusting to $315, both maintaining Buy ratings.

30 ott 2026, 23:41 UTC

News

Allegro Microsystems Inc. reported Q2 FY27 sales of $276.88M, exceeding expectations, and provided Q3 guidance of $278M to $288M, with shares modestly higher in after-market trading.

30 ott 2026, 23:41 UTC

News

BTIG suspended its Buy rating on IDEXX Laboratories, contributing to a decline in the stock's price during after-market hours.

30 ott 2026, 23:36 UTC

News

Capri Holdings Ltd reported Q2 profit of 42 cents per share and raised full-year EPS forecast to $2.20, with shares trading lower in after-market hours.

30 ott 2026, 23:31 UTC

News

McGrath RentCorp will replace Glaukos in the S&P 600 index at the market open on November 4, 2026, contributing to positive after-market price movement.

30 ott 2026, 23:26 UTC

News

JP Morgan maintains its Underweight rating on T. Rowe Price while raising the price target to $107; TD Cowen lowers its target to $96.

30 ott 2026, 23:26 UTC

News

Citigroup reaffirms Buy rating on Fortrea Holdings Inc and raises price target to $27, according to a report published today.

30 ott 2026, 23:21 UTC

News

Compass Inc. faces a class action lawsuit from Pomerantz LLP, alleging securities fraud related to its merger with Anywhere Real Estate Inc.

30 ott 2026, 23:16 UTC

News

JP Morgan maintains Neutral rating on Dexcom Inc and raises its price target to $85, reflecting the company's market position and growth potential.

30 ott 2026, 23:11 UTC

News

Pomerantz LLP has filed a class action lawsuit against The Chemours Company, alleging misleading statements and violations of federal securities laws.

30 ott 2026, 23:11 UTC

News

Cantor Fitzgerald identifies Binance's $6.3 billion hack as a potential buying opportunity for crypto-linked stocks, including Strategy Inc., amid recovery confidence.

30 ott 2026, 23:06 UTC

News

Uranium Energy Corp. shares declined in after-market hours, reflecting broader sector pressures despite analysts noting tightening supply in the uranium market.

30 ott 2026, 23:06 UTC

News
Social Media

S&P Global Ratings revised its outlook on Meta Platforms, Inc. to negative, citing uncertainty over capital expenditures and projected free operating cash flow deficits.

30 ott 2026, 23:06 UTC

News
Social Media

eBay expands managed shipping program amid seller eligibility concerns.

30 ott 2026, 23:06 UTC

News
Social Media

Coinbase Global, Inc. received an Overweight rating from JP Morgan, which lowered its price target to $187 amid security concerns following the $6.3 billion Binance hack.

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

38.78% in crescita

Previsioni per 12 mesi

Media 18.25 USD  38.78%

Alto 18.5 USD

Basso 18 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

2

Acquista

0

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat